Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Luke Walker, a director at Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently acquired additional shares of the company’s common stock. According to a recent SEC filing, Walker purchased 14,200 shares on January 31, 2025, at an average price of $1.7582 per share. The purchase comes as the stock trades near its 52-week low of $1.62, significantly below its 52-week high of $18.07. This transaction amounted to a total investment of approximately $24,966. Following this acquisition, Walker’s total direct ownership in the company increased to 86,681 shares. Zentalis Pharmaceuticals, based in San Diego, focuses on the development of small molecule therapeutics targeting cancer. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 7.29, though analysts do not expect profitability this year. The stock’s technical indicators suggest oversold conditions, with 4 analysts recently revising their earnings expectations upward.
In other recent news, Zentalis Pharmaceuticals has been the focus of several analyst adjustments. H.C. Wainwright cut the stock price target to $10, maintaining a Buy rating, while Jefferies lowered its target to $2.50, keeping a Hold rating. Oppenheimer also reduced its target to $10, upholding a Perform rating. These revisions follow updates on the development and regulatory status of Zentalis’ lead drug candidate, azenosertib.
Recent clinical studies have shown promising results for azenosertib in treating ovarian cancer, with an objective response rate (ORR) of approximately 35%. The company is set to conclude dose confirmation discussions with the FDA within 2025 and anticipates top-line data from the Denali Part 2 study by late 2026.
Zentalis also announced the addition of Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer, as it intensifies efforts to advance azenosertib. These appointments come alongside the company’s restructuring efforts, which included a 40% workforce cut, extending its cash runway into late 2027. These are the latest developments in Zentalis’ strategic focus on azenosertib and its potential as a groundbreaking treatment option for patients with ovarian cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.